ImmunityBio Future Growth

Future criteria checks 2/6

ImmunityBio is forecast to grow earnings and revenue by 59.2% and 48.4% per annum respectively while EPS is expected to grow by 59.7% per annum.

Key information

59.2%

Earnings growth rate

59.7%

EPS growth rate

Biotechs earnings growth	23.2%
Revenue growth rate	48.4%
Future return on equity	n/a
Analyst coverage	Low
Last updated	29 Apr 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

NasdaqGS:IBRX - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	521	-80	55	N/A	2
12/31/2025	277	-307	-181	N/A	2
12/31/2024	72	-437	-310	N/A	2
12/31/2023	1	-583	-397	-367	N/A
9/30/2023	1	-458	-384	-342	N/A
6/30/2023	1	-473	-387	-335	N/A
3/31/2023	1	-430	-406	-347	N/A
12/31/2022	0	-417	-437	-338	N/A
9/30/2022	1	-400	-409	-318	N/A
6/30/2022	1	-376	-393	-311	N/A
3/31/2022	1	-370	-364	-289	N/A
12/31/2021	1	-347	-308	-274	N/A
9/30/2021	0	-323	-283	-260	N/A
6/30/2021	0	-301	-241	-225	N/A
3/31/2021	1	-264	-210	-201	N/A
12/31/2020	1	-222	-173	-172	N/A
9/30/2020	2	-176	-136	-132	N/A
12/31/2019	2	-158	-156	-152	N/A
12/31/2018	3	-84	-76	-67	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: IBRX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: IBRX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: IBRX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: IBRX's revenue (48.4% per year) is forecast to grow faster than the US market (8.2% per year).

High Growth Revenue: IBRX's revenue (48.4% per year) is forecast to grow faster than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if IBRX's Return on Equity is forecast to be high in 3 years time

ImmunityBio Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Consensus revenue estimates increase by 639%, EPS downgraded

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

Forecast to breakeven in 2026

Consensus revenue estimates decrease by 54%, EPS upgraded

Consensus revenue estimates increase by 20%

Recent updates

Consensus revenue estimates increase by 639%, EPS downgraded

ImmunityBio, Inc., Annual General Meeting, Jun 11, 2024

ImmunityBio, Inc. Announces Positive Overall Survival Results of Anktiva Combined with Checkpoint Inhibitors in Non-Small Cell Lung Cancer

ImmunityBio, Inc. Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

ImmunityBio Lights Up: Anktiva's FDA Nod Shakes Up Bladder Cancer Battle

Insufficient new directors

Consensus revenue estimates increase by 25%

No longer forecast to breakeven

New minor risk - Profitability

New major risk - Financial position

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio Announces Data from A Phase 1 Pilot Study

ImmunityBio: Financial And Regulatory Risks Outweigh Anktiva's Promise

New major risk - Share price stability

ImmunityBio, Inc. Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the Trial

Forecast to breakeven in 2026

ImmunityBio: Buy Low Now Vs. Buy High Later

Immunitybio, Inc. Announces Findings from Patient-Reported Outcomes (PROs) of Participants in the Phase 2/3 Quilt 3.032 Study of N-803 Plus BCG

Consensus revenue estimates decrease by 54%, EPS upgraded

New major risk - Financial position

ImmunityBio, Inc. Announces First Data for Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-Tumor Activity

ImmunityBio, Inc. Announces U.S. Food and Drug Administration Accepts its BLA Resubmission as Complete and Sets New PDUFA Date

New major risk - Share price stability

ImmunityBio, Inc. Announces Biological License Application Resubmission for N-803 in BCG Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-Situ

New major risk - Shareholder dilution

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

ImmunityBio, Inc. announced that it has received $200 million in funding from Nant Capital, LLC

Consensus revenue estimates increase by 20%

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Jakubowitz Law Reminds Immunitybio Shareholders of A Lead Plaintiff Deadline of August 29, 2023

ImmunityBio, Inc. Appoints Enrique Diloné as Chief Technology Officer, Effective August 14, 2023

ImmunityBio, Inc. Announces Findings from a Phase 1 Study Showing Allogeneic Cytokine-Induced Memory-Like Natural Killer Cells

Pomerantz Law Firm Announces the Filing of a Class Action Against ImmunityBio, Inc. and Certain Officers – IBRX

Independent Director recently bought US$71k worth of stock

ImmunityBio, Inc., Annual General Meeting, Jun 13, 2023

ImmunityBio, Inc. Receives Complete Response Letter from the U.S. Food and Drug Administration Regarding Its Biologics License Application

First quarter 2023 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

President exercised options and sold US$183k worth of stock

ImmunityBio, Inc. announced that it expects to receive $50 million in funding

Price target decreased to US$9.00

High number of new directors

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

ImmunityBio: PDUFA Pending

Second quarter 2022 earnings released: US$0.24 loss per share (vs US$0.23 loss in 2Q 2021)

ImmunityBio: Compelling Data In Bladder Cancer, Yet Funding Issues Remain

Consensus forecasts updated

ImmunityBio, Inc. Announces FDA Acceptance of Biologics License Application for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma in Situ

ImmunityBio, Inc. Announces Quilt Trial Results for BCG-Unresponsive Bladder Cancer and Advanced Metastatic Pancreatic Cancer

ImmunityBio: Ready To Shift Gears After Long-Awaited BLA Submission

ImmunityBio, Inc. Submits Biologics License Application for N-803 Plus Bcg for Patients with Bcg-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma in Situ

First quarter 2022 earnings: EPS and revenues miss analyst expectations

ImmunityBio, Inc., Annual General Meeting, Jun 14, 2022

Price target decreased to US$20.00

High number of new directors

Immunitybio Announces First Participants Have Been Enrolled in Lung-MAP Trial Studying Anktiva to Activate NK and T Cells in Non-Small Cell Lung Cancer

ImmunityBio: Extensive Pipeline, NDA Expected For Anktiva This Quarter

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. Announces Study Results That Further Demonstrate the Potential for Use of Memory-Like Cytokine-Enriched Natural Killer (m-ceNK) Cells for the Treatment of Cancer

ImmunityBio, Inc. (NasdaqGS:IBRX) completed the acquisition of Dunkirk Manufacturing Facility and Certain Related Assets of Athenex, Inc. (NasdaqGS:ATNX).

ImmunityBio, Inc. Announces Positive Data from its Late-Stage Bladder Cancer Trial

President exercised options and sold US$159k worth of stock

ImmunityBio, Inc. Announces Promising Clinical Study Results for Kick and Kill HIV Cure Strategy to Reduce HIV Viral Load with Anktiva (N-803) Therapy

ImmunityBio, Inc. Announces Interim Results in its Metastatic Pancreatic Cancer Trial

ImmunityBio: Company Leaves 2021 On A High-Note; Share Price Still Falls Flat

ImmunityBio, Inc. Announces Updates on Its Clinical Year-End Review of Strategic Milestones

Third quarter 2021 earnings released: US$0.22 loss per share (vs US$0.17 loss in 3Q 2020)

ImmunityBio: Demoralization Of The Bulls By Deflating The Share Price

ImmunityBio, Inc. Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with A Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-Free in Phase 2/3 Trial